Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Hoskinson says Midnight crypto will outgrow Zcash—yet NIGHT still tracks it

Hoskinson says Midnight crypto will outgrow Zcash—yet NIGHT still tracks it

AMBCryptoAMBCrypto2026/09/28 15:21
By:AMBCrypto

Cardano founder Charles Hoskinson suggested that Midnight will be bigger than ZCash in future, setting up a comparison against one of privacy’s more renowned networks and putting the newer privacy-focused network under considerable scrutiny. 

Following the prediction, NIGHT has seen more attention drawn to it, but the picture in terms of market reality indicates something more complicated. Midnight remains far smaller than Zcash, and the recent price data suggests that the two assets are largely moving in the same direction.

Why Hoskinson expects Midnight to grow

@media only screen and (min-width: 0px) and (min-height: 0px) { div[id^="bsa-zone_1774359638628-7_123456"] { min-height: 50px; transition: min-height 0.3s ease; } } @media only screen and (min-width: 640px) and (min-height: 0px) { div[id^="bsa-zone_1774359638628-7_123456"] { min-height: 90px; } }
AD

“Midnight will be bigger than ZCash,” Hoskinson wrote, referring to several features which he thinks will set the network apart. 

Selective privacy is the idea behind the Midnight system. Not everything needs to be made public, and not everything must be explicitly kept hidden; the users instead can have control over revealing only specific information. 

For instance, a person can tell others that they meet the age requirement without giving away their birth date or any other information.

In addition to that, several additional plans for Midnight were laid out by Charles Hoskinson, which include the support of apps and private software agents across many major blockchains. 

The whole focus of the Cardano network was for people and programs to use financial services without feeling the need to reveal their private data that the system does not need.

However, “bigger” remains open to interpretation. Hoskinson did not say whether he was referring to price, market value, user numbers, or activity on the network. Or does he refer to 2027 as a development milestone rather than a firm deadline for overtaking Zcash? 

NIGHT price approaches its next test

NIGHT was trading near the

$0.0269
price level at the time of this writing, slightly lower for the day after reaching around the
$0.0279
price level.

It has recovered from the lows of August to now be trading over some of its shorter-term price markers. This means that recovery has had some strength to it, though it is still within its wider down channel.

The nearest major blockade stands in the

$0.028
vicinity. A breakout beyond that mark could see the price challenging the
$0.030
level, followed by a sterner test at
$0.033
. If sellers gain the upper hand, expect first cushion near the
$0.025
price level and another cushion between the
$0.023 and $0.024
price areas.

One particularly interesting detail is NIGHT’s

20-day correlation with Zcash
, which stood at
0.87
. What this means is that the two assets have recently tended to rise and fall together.

However, that does not suggest that Zcash influences NIGHT’s price. Both can merely represent the same increasing attention that privacy-focused cryptos are seeing. This causes a strange dynamic. Midnight acts as the upcoming Zcash competitor, yet its token still trades similarly to Zcash.

The size difference also remains substantial. Recent market snapshots placed Midnight near

$443 million and Zcash around $26.2 billion
. At those valuations, NIGHT would need to grow roughly
59-fold
to match Zcash, and this is assuming Zcash itself stood still.

Final Summary

  • NIGHT must clear $0.028 before its recovery can make further progress.
  • Hoskinson’s prediction is ambitious, but what ‘bigger’ means is still open to interpretation.

 

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify

In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.

华尔街见闻•2026/11/06 15:01

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23